Research programme: inflammatory disease therapeutics - Janssen Biotech/X-Chem

Drug Profile

Research programme: inflammatory disease therapeutics - Janssen Biotech/X-Chem

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator X-Chem
  • Developer Janssen Biotech; X-Chem
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 15 Feb 2017 X-Chem expands collaboration with Janssen Biotech for the development of small molecules for the treatment of Inflammatory diseases
  • 30 Mar 2016 X-Chem enters into a licensing agreement with Janssen Biotech for protein inhibitor programme of Inflammatory disease
  • 09 Jan 2015 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top